+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drugs in Development, 2021

  • PDF Icon

    Drug Pipelines

  • March 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5331251
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

According to the recently published report 'Indoleamine 2,3 Dioxygenase 1 - Drugs in Development, 2021'; Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 38 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes.

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.

The report 'Indoleamine 2,3 Dioxygenase 1 - Drugs in Development, 2021' outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 6, 1, 16 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Infectious Disease, Metabolic Disorders and Musculoskeletal Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Bladder Cancer, Head And Neck Cancer, Metastatic Melanoma, Colon Cancer, Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adrenal Gland Cancer, Alopecia, Breast Cancer, Cervical Cancer, Colon Carcinoma, Endometrial Cancer, Ependymoma, Gallbladder Cancer, Glioma, Gliosarcoma, Hematological Tumor, High-Grade Glioma, Kaposi Sarcoma, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medulloblastoma, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Nasopharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcopenia, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Type 1 Diabetes (Juvenile Diabetes), Ureter Cancer and Urethral Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
  • The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview
  • Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
  • Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
  • Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
  • Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
  • Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products
  • Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products
  • Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
  • Appendix

List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by BeiGene Ltd, 2021
  • Pipeline by BirchBioMed Inc, 2021
  • Pipeline by Bristol-Myers Squibb Co, 2021
  • Pipeline by CanBas Co Ltd, 2021
  • Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2021
  • Pipeline by Emcure Pharmaceuticals Ltd, 2021
  • Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Pipeline by Gerologix Inc, 2021
  • Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2021
  • Pipeline by Hutchison MediPharma Ltd, 2021
  • Pipeline by Incyte Corp, 2021
  • Pipeline by IO Biotech ApS, 2021
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Pipeline by Kyowa Kirin Co Ltd, 2021
  • Pipeline by Lumos Pharma Inc, 2021
  • Pipeline by Luye Pharma Group Ltd, 2021
  • Pipeline by Merck & Co Inc, 2021
  • Pipeline by Nammi Therapeutics Inc, 2021
  • Pipeline by Netherlands Translational Research Center BV, 2021
  • Pipeline by Orpheris Inc, 2021
  • Pipeline by Phenex Pharmaceuticals AG, 2021
  • Pipeline by Regen BioPharma Inc, 2021
  • Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021
  • Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2021
  • Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021
  • Pipeline by Syntekabio Inc, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • BeiGene Ltd
  • BirchBioMed Inc
  • Bristol-Myers Squibb Co
  • CanBas Co Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Emcure Pharmaceuticals Ltd
  • F. Hoffmann-La Roche Ltd
  • Gerologix Inc
  • Guangzhou BeBetter Medicine Technology Co Ltd
  • Hutchison MediPharma Ltd
  • Incyte Corp
  • IO Biotech ApS
  • Jiangsu Hengrui Medicine Co Ltd
  • Kyowa Kirin Co Ltd
  • Lumos Pharma Inc
  • Luye Pharma Group Ltd
  • Merck & Co Inc
  • Nammi Therapeutics Inc
  • Netherlands Translational Research Center BV
  • Orpheris Inc
  • Phenex Pharmaceuticals AG
  • Regen BioPharma Inc
  • Secarna Pharmaceuticals GmbH & Co KG
  • Shanghai De Novo Pharmatech Co Ltd
  • Shenzhen Chipscreen Biosciences Co Ltd
  • Syntekabio Inc